Emmaus Life Sciences Inc.(NASDAQ:EMMA) stock News

EMMA Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Emmaus Life Sciences, Inc.

Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements

3 months ago - By: Emmaus Life Sciences, Inc.

Emmaus Life Sciences Reports 2024 Financial Results

6 months ago - By: Emmaus Life Sciences, Inc.

Emmaus Life Science Reports Grant of Endari Market Exclusivity In Kingdom of Saudi Arabia

10 months ago - By: Benzinga - Mentions: WYY PMN

ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying

a year ago - By: Emmaus Life Sciences, Inc.

Emmaus Life Sciences Reports Delayed Filing of Annual Report

a year ago - By: Benzinga - Mentions: GEG ETST

Great Elm Group And 2 Other Stocks Under $2 Insiders Are Buying

2 years ago - By: Emmaus Life Sciences, Inc.

Emmaus Life Sciences Reports Management Changes

2 years ago - By: Emmaus Life Sciences, Inc.

Emmaus Life Sciences Provides Interim Shipment Data

3 years ago - By: Emmaus Life Sciences, Inc.

Dr. Niihara Meets with Local Indian Governor

a year ago - By: Emmaus Life Sciences, Inc.

Emmaus Life Sciences recibe la autorización de comercialización para Puerto Rico

a year ago - By: Emmaus Life Sciences, Inc.

Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico

2 years ago - By: Emmaus Life Sciences, Inc.

Emmaus Life Sciences Reports Q3 2023 Financial Results

2 years ago - By: Emmaus Life Sciences, Inc.

Emmaus Life Sciences Reports Q2 2023 Financial Results

3 years ago - By: Emmaus Life Sciences, Inc.

Endari® Receives Kuwaiti Marketing Authorization

2 years ago - By: Emmaus Life Sciences, Inc.

Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman

2 years ago - By: Emmaus Life Sciences, Inc.

Emmaus Life Sciences Receives Endari® Marketing Authorization from the Bahrain NHRA

2 years ago - By: Emmaus Life Sciences, Inc.

Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update

2 years ago - By: Emmaus Life Sciences, Inc.

Emmaus Life Sciences Reports 2022 Financial Results and Provides Business Update

3 years ago - By: Emmaus Life Sciences, Inc.

Dr. Niihara Feted by Indian Government in Recognition of the Development of Endari®

3 years ago - By: Emmaus Life Sciences, Inc.

Emmaus Life Sciences Receives Endari® Marketing Authorization from the Qatar Ministry of Public Health

3 years ago - By: Emmaus Life Sciences, Inc.

Emmaus Life Sciences Reports Q3 2022 Financial Results and Provides Business Update

3 years ago - By: Emmaus Life Sciences, Inc.

Emmaus Life Sciences Announces Collaboration with Kier (Junior) Spates to Share Personal Experience with Sickle Cell Disease and Endari®

3 years ago - By: Emmaus Life Sciences, Inc.

Emmaus Life Sciences Reports Q2 2022 Financial Results and Provides Business Update

3 years ago - By: Emmaus Life Sciences, Inc.

Emmaus Life Sciences Announces Engagement of Strategic Business Relations and Professional Services Advisor

3 years ago - By: Emmaus Life Sciences, Inc.

Emmaus Life Sciences Reports Q1 2022 Financial Results and Provides Business Update

3 years ago - By: Emmaus Life Sciences, Inc.

Emmaus Life Sciences to Present at Investor Conferences in May

3 years ago - By: Emmaus Life Sciences, Inc.

Emmaus Life Sciences Reports 2021 Financial Results and Provides Business Update

3 years ago - By: Emmaus Life Sciences, Inc.

Emmaus Life Sciences Receives U.A.E. Marketing Authorization for Endari®

3 years ago - By: Emmaus Life Sciences, Inc.

Emmaus Life Sciences Inc. (EMMA) Stock News

EMMA Latest News, Press Relases and Analysis

Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements

Emmaus Life Sciences Reports 2024 Financial Results

Emmaus Life Science Reports Grant of Endari Market Exclusivity In Kingdom of Saudi Arabia

ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying

Emmaus Life Sciences Reports Delayed Filing of Annual Report

Great Elm Group And 2 Other Stocks Under $2 Insiders Are Buying

Emmaus Life Sciences Reports Management Changes

Emmaus Life Sciences Provides Interim Shipment Data

Dr. Niihara Meets with Local Indian Governor

Emmaus Life Sciences recibe la autorización de comercialización para Puerto Rico

Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico

Emmaus Life Sciences Reports Q3 2023 Financial Results

Emmaus Life Sciences Reports Q2 2023 Financial Results

Endari® Receives Kuwaiti Marketing Authorization

Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman

Emmaus Life Sciences Receives Endari® Marketing Authorization from the Bahrain NHRA

Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update

Emmaus Life Sciences Reports 2022 Financial Results and Provides Business Update

Dr. Niihara Feted by Indian Government in Recognition of the Development of Endari®

Emmaus Life Sciences Receives Endari® Marketing Authorization from the Qatar Ministry of Public Health

Emmaus Life Sciences Reports Q3 2022 Financial Results and Provides Business Update

Emmaus Life Sciences Announces Collaboration with Kier (Junior) Spates to Share Personal Experience with Sickle Cell Disease and Endari®

Emmaus Life Sciences Reports Q2 2022 Financial Results and Provides Business Update

Emmaus Life Sciences Announces Engagement of Strategic Business Relations and Professional Services Advisor

Emmaus Life Sciences Reports Q1 2022 Financial Results and Provides Business Update

Emmaus Life Sciences to Present at Investor Conferences in May

Emmaus Life Sciences Reports 2021 Financial Results and Provides Business Update

Emmaus Life Sciences Receives U.A.E. Marketing Authorization for Endari®

Emmaus Life Sciences' Real World Data on Endari® Accepted for E-Poster at the 62nd Annual Scientific Meeting of the British Society for Haematology